
## **Ophthalmic Images**


## Choroidal Detachment After Intravitreal Injection of Faricimab

Etienne M. Schönbach, MD; William R. Freeman, MD





**B** B-scan ultrasonography



**Figure.** Suprachoroidal hemorrhage after intravitreal faricimab injection with a 30-gauge needle. A, Fundus widefield pseudocolor photography at day 1 after intravitreal injection of faricimab demonstrates a new choroidal detachment (arrowheads) and preexisting macular atrophy and drusen. B, Ophthalmic B-scan ultrasonography demonstrates that the choroidal detachment has underlying hyperechogenic material (arrowheads), suggesting a hemorrhagic process.

A 70-year-old White emmetropic female patient with neovascular age-related macular degeneration had received aflibercept intravitreal injections without complications over years. One day af-



CME at jamacmelookup.com

ter an uneventful first injection of faricimab using a superonasal pars plana approach and a 30-gauge needle, she pre-

sented with pain and a subjective visual field defect. She had stable visual acuity of 20/400 OS, hypotony (intraocular pressure of 3 mm Hg), and a suprachoroidal hemorrhage (SCH) (Figure). Patching and

application of tobramycin-dexamethasone ophthalmic ointment were recommended. The hypotony resolved within days, and the SCH resolved 2 months after injection. Visual acuity remained 20/400 OS. Suprachoroidal hemorrhages after intravitreal injections using small-gauge needles have been reported but are rare. <sup>1-3</sup> Risk factors for SCH include anticoagulation <sup>4</sup> and high myopia, <sup>5</sup> but these were not present in this patient, where postinjection ocular hypotony may have been the initial event leading to rupture of ciliary artery branches <sup>6</sup> with subsequent SCH. This limited, nonappositional case of SCH resolved without surgery.

## ARTICLE INFORMATION

**Author Affiliations:** Jacobs Retina Center at the Shiley Eye Institute, University of California, San Diego, San Diego.

Corresponding Author: Etienne Schönbach, MD, Jacobs Retina Center at the Shiley Eye Institute, University of California, San Diego, 9415 Campus Point Dr, La Jolla, CA 92093 (eschoenbach@hotmail.de).

**Conflict of Interest Disclosures:** None reported. **Additional Contributions:** We thank the patient for granting permission to publish this information.

## **REFERENCES**

1. Jones RK, Khan IJ, Habal S. Suprachoroidal haemorrhage following intravitreal injection.

Postgrad Med J. 2017;93(1095):56. doi:10.1136/postgradmedj-2016-134144

- 2. Brouzas D, Koutsandrea C, Moschos M, Papadimitriou S, Ladas I, Apostolopoulos M. Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by contralateral sympathetic ophthalmia. *Clin Ophthalmol*. 2009;3:457-459. doi:10.2147/ OPTH.S4641
- 3. Meyer CH, Brinkmann CK, Helb HM. Choroidal detachment after an uneventful intravitreal injection. *J Ocul Pharmacol Ther*. 2010;26(3):305-307. doi:10.1089/jop.2009.0128
- **4**. Chandra A, Xing W, Kadhim MR, Williamson TH. Suprachoroidal hemorrhage in pars plana

vitrectomy: risk factors and outcomes over 10 years. *Ophthalmology*. 2014;121(1):311-317. doi:10.1016/j.ophtha.2013.06.021

- 5. Tabandeh H, Sullivan PM, Smahliuk P, Flynn HW Jr, Schiffman J. Suprachoroidal hemorrhage during pars plana vitrectomy—risk factors and outcomes. *Ophthalmology*. 1999;106(2):236-242. doi:10.1016/S0161-6420(99)90062-3
- **6**. Manschot WA. The pathology of expulsive hemorrhage. *Am J Ophthalmol*. 1955;40(1):15-24. doi:10.1016/0002-9394(55)92116-4